First Clinical Trial Exploring Effects of a New, Immune System-Based Agent in Advanced Melanoma


October 6, 2010

Penn Medicine News Release

PHILADELPHIA -- Researchers at the University of Pennsylvania School of Medicine and Immunocore Limited, Oxford, UK, today announced that a targeted agent that may have a role in treating advanced metastatic melanoma in the future has received Investigational New Drug (IND) approval and is opening enrollment for clinical trials in the UK and USA.

Melanoma is a form of skin cancer that accounts for approximately five percent of cases but causes the vast majority of skin-cancer deaths. The American Cancer Society estimates that over 68,000 new melanomas will be diagnosed in the US during 2010 and 8,700 deaths from this disease will occur. Incidence rates for melanoma have increased in the last thirty years, and unlike other common cancers, melanoma has a wide age of distribution. Read More

Learn More About: